​

Atrium Therapeutics (RNA) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Atrium Therapeutics Revenue Highlights

Latest Revenue (Y)

$18.75M

Latest Revenue (Q)

$12.47M

Main Segment (Y)

Reportable Segment

Atrium Therapeutics Revenue by Period

Atrium Therapeutics Revenue by Year

DateRevenueChange
2025-12-31$18.75M72.11%
2024-12-31$10.90M13.99%
2023-12-31$9.56M3.64%
2022-12-31$9.22M-1.09%
2021-12-31$9.33M37.41%
2020-12-31$6.79M192.67%
2019-12-31$2.32M511.87%
2018-12-31$379.00K-

Atrium Therapeutics generated $18.75M in revenue during NA 2025, up 72.11% compared to the previous quarter, and up 276.34% compared to the same period a year ago.

Atrium Therapeutics Revenue by Quarter

DateRevenueChange
2025-09-30$12.47M224.28%
2025-06-30$3.85M144.56%
2025-03-31$1.57M-47.09%
2024-12-31$2.97M27.27%
2024-09-30$2.34M14.23%
2024-06-30$2.04M-42.28%
2024-03-31$3.54M61.56%
2023-12-31$2.19M-22.18%
2023-09-30$2.82M21.68%
2023-06-30$2.32M3.72%
2023-03-31$2.23M-19.36%
2022-12-31$2.77M11.56%
2022-09-30$2.48M13.96%
2022-06-30$2.18M21.34%
2022-03-31$1.79M-3.08%
2021-12-31$1.85M-14.38%
2021-09-30$2.16M-17.03%
2021-06-30$2.61M-3.59%
2021-03-31$2.70M26.24%
2020-12-31$2.14M22.68%
2020-09-30$1.75M13.30%
2020-06-30$1.54M13.48%
2020-03-31$1.36M-6.02%
2019-12-31$1.45M122.31%
2019-09-30$650.00K190.18%
2019-06-30$224.00K100.00%
2019-03-31--

Atrium Therapeutics generated $12.47M in revenue during Q3 2025, up 224.28% compared to the previous quarter, and up 610.02% compared to the same period a year ago.

Atrium Therapeutics Revenue Breakdown

Atrium Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24
Reportable Segment$18.75M$10.90M

Atrium Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Reportable Segment (100.00%).

Quarterly Revenue by Product

Product/ServiceDec 25Sep 25Jun 25Mar 25
Reportable Segment$860.00K$12.47M$3.85M$1.57M

Atrium Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Reportable Segment (100.00%).

RNA Revenue FAQ

What is Atrium Therapeutics’s yearly revenue?

Atrium Therapeutics's yearly revenue for 2025 was $18.76M, representing an increase of 72.11% compared to 2024. The company's yearly revenue for 2024 was $10.9M, representing an increase of 13.99% compared to 2023. RNA's yearly revenue for 2023 was $9.56M, representing an increase of 3.64% compared to 2022.

What is Atrium Therapeutics’s quarterly revenue?

Atrium Therapeutics's quarterly revenue for Q3 2025 was $12.48M, a 224.28% increase from the previous quarter (Q2 2025), and a 434.03% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $3.85M, a 144.56% increase from the previous quarter (Q1 2025), and a 88.12% increase year-over-year (Q2 2024). RNA's quarterly revenue for Q1 2025 was $1.57M, a -47.09% decrease from the previous quarter (Q4 2024), and a -55.60% decrease year-over-year (Q1 2024).

What is Atrium Therapeutics’s revenue growth rate?

Atrium Therapeutics's revenue growth rate for the last 3 years (2023-2025) was 96.18%, and for the last 5 years (2021-2025) was 101.10%.

What are Atrium Therapeutics’s revenue streams?

Atrium Therapeutics's revenue streams in c 25 are Reportable Segment

What is Atrium Therapeutics’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Atrium Therapeutics was Reportable Segment. This segment made a revenue of $18.76M, representing 100.00% of the company's total revenue.